UCLA's study identifies distinct Alzheimer's disease trajectories, emphasizing the role of shared risk factors in early detection and targeted interventions.

The newly recommended dosing schedule significantly lowered ARIA-E rates compared to the original dosing schedule, adding to the established safety profile of the treatment "We are confident that this ...